Drug Profile

ALE P02

Alternative Names: ALE-P02; ALE.P02

Latest Information Update: 21 Nov 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Alentis Therapeutics
Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
Mechanism of Action Tubulin inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

18 Nov 2024 ALE P02 receives Fast track designation from the US FDA for squamous cell cancer
02 Oct 2024 US FDA approves IND application for ALE.P02 in Squamous cell cancer
02 Oct 2024 Alentis Therapeutics plans a phase I/II trial for Squamous cell cancer in USA(Parenteral) in the first quarter of 2025

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com